| Drug Name |
Esmolol |
| Drug ID |
BADD_D00813 |
| Description |
Esmolol, commonly marketed under the trade name Brevibloc, is a cardioselective beta-1 receptor blocker. It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses. It works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of heart contractions. Esmolol prevents the action of two naturally occurring substances: epinephrine and norepinephrine. |
| Indications and Usage |
For the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Also used in noncompensatory sinus tachycardia where the rapid heart rate requires specific intervention. |
| Marketing Status |
approved |
| ATC Code |
C07AB09 |
| DrugBank ID |
DB00187
|
| KEGG ID |
D07916
|
| MeSH ID |
C036604
|
| PubChem ID |
59768
|
| TTD Drug ID |
D03XTC
|
| NDC Product Code |
Not Available |
| UNII |
MDY902UXSR
|
| Synonyms |
esmolol | Brevibloc | esmolol hydrochloride | ASL 8052 | ASL-8052 |
